COLLPLANT BIOTECHNOLOGIESNEW ($CLGN) posted quarterly earnings results on Wednesday, August 20th. The company reported earnings of -$0.28 per share, missing estimates of -$0.14 by $0.14. The company also reported revenue of $180,000, missing estimates of $2,594,880 by $-2,414,880.
You can see Quiver Quantitative's $CLGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COLLPLANT BIOTECHNOLOGIESNEW Hedge Fund Activity
We have seen 10 institutional investors add shares of COLLPLANT BIOTECHNOLOGIESNEW stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC added 275,082 shares (+inf%) to their portfolio in Q2 2025, for an estimated $374,111
- ANSON FUNDS MANAGEMENT LP added 159,401 shares (+inf%) to their portfolio in Q2 2025, for an estimated $216,785
- VILLERE ST DENIS J & CO LLC added 63,000 shares (+13.0%) to their portfolio in Q2 2025, for an estimated $85,680
- AMH EQUITY LTD added 35,849 shares (+28.7%) to their portfolio in Q2 2025, for an estimated $48,754
- RENAISSANCE TECHNOLOGIES LLC added 31,300 shares (+303.9%) to their portfolio in Q2 2025, for an estimated $42,568
- UBS GROUP AG removed 24,074 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $32,740
- PINNACLE ASSOCIATES LTD added 18,000 shares (+3.7%) to their portfolio in Q2 2025, for an estimated $24,480
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
COLLPLANT BIOTECHNOLOGIESNEW Analyst Ratings
Wall Street analysts have issued reports on $CLGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 05/30/2025
To track analyst ratings and price targets for COLLPLANT BIOTECHNOLOGIESNEW, check out Quiver Quantitative's $CLGN forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
